Summary
A total of 106 patients with inflammatory carcinoma of the breast underwent combined-modality treatment consisting of doxorubincin-containing chemotherapy. All patients received three cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) before local therapy. From 1974 to 1977 (group A), primary radiotherapy was the local treatment modality and chemotherapy was given for a total of 24 months. From 1978 to 1981 (group B), mastectomy became the primary local treatment modality and FAC was reinstituted within 10–14 days after surgery; after completion of FAC, consolidation radiotherapy was given. From 1982 to 1986 (group C), vincristine and prednisone were added to FAC, and doxorubicin was given by continuous infusion. The median follow-up of the three groups was 56 months. For patients alive at the time of analysis, median follow-ups were 141, 111, and 49 months in groups A, B, and C, respectively. Disease-free survival at 5 years was 35%, 22%, and 41% for groups A, B, and C, respectively, and respective overall survival at 5 years was 37%, 30%, and 48%. Mastectomy in addition to radiotherapy resulted in local control rates similar to those obtained with radiotherapy alone, but this approach would result in fewer late sequelae of high-dose irradiation and provided histologic staging for chemotherapy response. The patients treated on protocol C had slightly better disease-free and overall survival, but the differences were not statistically significant. The 5-year disease-free survival of patients achieving a clinical complete remission (CR) or partial remission (PR) was superior to that of patients whose response was less than a PR. There was no episode of doxorubicin-related cardiac toxicity in group C. Combined-modality treatment for inflammatory carcinoma of the breast resulted in improved survival.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barber KW, Dockerty MB, Clagett OT (1961) Inflammatory carcinoma of the breast. Surg Gynecol Obstet 112: 406–410
Barker JL, Nelson AJ, Montague ED (1976) Inflammatory carcinoma of the breast. Radiology 121: 173–176
Barker JL, Montague ED, Peters LJ (1980) Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 45: 625–629
Bruckman JE, Harris JR, Levene MB, Chaffey GJ, Hellman S (1979) Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 43: 985–993
Brun B, Otmezguine Y, Feuilhade F, Gulien M, Lebourgeois GP, Calitchi E, Roucayrol AM, Janem J, Huart G, Pierguin B (1988) Treatment and mastectomy versus breast conservation. Cancer 61: 1096–1103
Bruton GV, Cox EB, Leight GS, Presnitz LR, Aglehart GD, Olsen JA, Seigler HF, Hart LL (1987) Inflammatory breast carcinoma: effective multimodal approach. Arch Surg 122: 1329–1332
Buzdar AU, Montague ED, Barker JL, Hortobagyi JN, Blumenschein JR (1981) Management of inflammatory carcinoma of the breast with a combined modality approach — an update. Cancer 47: 2537–2542
Buzdar AU, Hortobagyi J, Frye D, Ames F, Singletary S, McNeese M, Montagne E (1987) Inflammatory carcinoma of the breast: preliminary results of a combined modality approach. Proceedings of the 15th International Congress of Chemotherapy, Tokyo, pp July 19–24, 438–440
Chevallir B, Asselain B, Kunlin A, Veyret C, Bastit P, Iraic Y (1987) Inflammatory breast cancer: determination of prognostic factors by univariate and multivariate analysis. Cancer 60: 897–902
Dao TL, McCarthy JD (1957) Treatment of inflammatory carcinoma of the breast. Surg Gynecol Obstet 105: 289–294
DeLarue JC, May-Levin F, Mouriesse H, Contesso, J, Sancho-Jarnier H (1981) Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumors of the human breast. Br J Cancer 44: 911–916
DeLena M, Varini M, Zucali R, Rovini D, Viganetti J, Valagussa U, Bonadonna J (1981) Multimodality treatment for advanced breast cancer. Cancer Clin Trials 4: 229–236
DeVita VT, Hellman S, Rosenberg SA (1989) Important advances in oncology 1989. J. B. Lippincott, Philadelphia, pp 129–150
Ellis DL, Teitelbaum SL (1984) Inflammatory carcinoma of the breast: a pathologic definition. Cancer 33: 1045–1047
Fastenberg NA, Buzdar AU, Montague ED, Gessup GM, Martin RJ, Hortobagyi JN, Blumenschein JR (1985) Management of inflammatory carcinoma of the breast: a combined modality approach. Am J Clin Oncol 8: 134–141
Fields JN, Kuske RR, Perez CA, Sineberg BB, Bartlett N (1989) Prognostic factors in inflammatory breast cancer. Cancer 63: 1225–1232
Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrics 52: 203–223
Haagensen CD (1986) Inflammatory carcinoma. In: Haagensen CD (eds) Disease of the breast, 3rd edn. WB Saunders Philadelphia, pp 808–814
Hagelberg RS, Jolly PC, Anderson RP (1984) Role of surgery in the treatment of inflammatory breast carcinoma. Am J Surg 125–131
Harvey HA, Lipton A, Lawrence BV (1982) Estrogen receptor in inflammatory breast cancer. J Surg Oncol 21: 42–44
Hayward JL, Carbone PP, Heuson JC, Kumavka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer: a project of the programme on clinical oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39: 1289–1294
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Knight CD, Martin JK, Welch JS, Angle GN, Jaffey JA, Martinez A (1986) Surgical considerations after chemotherapy and radiation therapy for inflammatory breast cancer. Surgery 99: 385–391
Levine PH, Steinhorn SC, Ries LG, Aron JL (1985) Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) programs. JNCI 14: 291–297
Morris DM (1983) Mastectomy in the treatment of patients with inflammatory breast cancer. J Surg Oncol 23: 255–258
Richards FJ, Lewison EF (1961) Inflammatory carcinoma of the breast. Surg Gynecol Obstet 113: 729
Rouesee J, Friedman S, Sarrazin D, Mouriesse H, Le Chevalier T, Arriagada R, Spielmann M, Papacharalambous A, May-Levin F (1986) Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institute Gustave-Roussy. J Clin Oncol 4: 1765–1771
Rubens RD, Sexton R, Tong D, Winter PJ, Knight RK, Hayward JL (1980) Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer 16: 351–356
Schafer P Alberto D, Forni M, Olradovic D, Pipard J, Kraner F (1987) Surgery as a part of a combined modality approach for inflammatory breast cancer. Cancer 59: 1063–1067
Swain SM, Sorace RA, Baley CS, Danforth DN jr., Bader J Wesley MN, Steinberg SM, Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancei. Cancer Res 47: 3889–3894
Traves N (1959) The inoperability of inflammatory carcinoma of the breast. Surg Gynecol Obstet 109: 240–242
Wang CC, Griscom NT (1964) Inflammatory carcinoma of the breast: results following orthovoltage and supervoltage radiation therapy. Clin Radiol 15: 168–174
Zucali R, Uslenghi C, Kenda R, Bonadonna J (1976) History and survival of inoperable breast cancer treated with radiotherapy followed by radical mastectomy. Cancer 37: 1422–1431
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koh, E.H., Buzdar, A.U., Ames, F.C. et al. Inflammatory carcinoma of the breast: results of a combined-modality approach — M. D. Anderson Cancer Center experience. Cancer Chemother. Pharmacol. 27, 94–100 (1990). https://doi.org/10.1007/BF00689090
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689090